Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19
Summary
Ideal new treatments for Novel Coronavirus-19 (COVID-19) would help halt the progression disease in patients with mild disease prior to the need for artificial respiration (ventilators), and also provide a rescue treatment for patients with severe disease, while also being affordable and available in quantities sufficient to treat large numbers of infected people. Low doses of Naltrexone, a drug approved for treating alcoholism and opiate addiction, as well as Ketamine, a drug approved as an anesthetic, may be able to interrupt the inflammation that causes the worst COVID-19 symptoms and prove an effective new treatment. This study will investigate their effectiveness in a randomized, blinded trial versus standard treatment plus placebo.
Timeline
- Start
- 2020-04-29
- Primary completion
- 2021-04-01
- Completion
- 2021-04-01
Outcome
Outcome not reported
Stopped (Enrollment): “Because of the decrease in COVID cases, enrollment is extremely low. Given the current study design, it is not possible to gather data necessary to answer the question about whether study treatment reduces mortality”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ketamine | Small molecule | 0.15 mg/kg | Intravenous |
| Subject | Ketamine | Small molecule | 0.3 mg/kg | Intravenous |
| Subject | Naltrexone | Small molecule | 4.5 mg | Oral |